Health Care & Life Sciences » Pharmaceuticals | Dongsung Pharmaceutical Co. Ltd.

Dongsung Pharmaceutical Co. Ltd. | Income Statement

Fiscal year is January-December. All values KRW Millions.
2013
2014
2015
2016
2017
2018
Sales/Revenue
75,175
73,158
74,660
79,721
82,385
91,913
Cost of Goods Sold (COGS) incl. D&A
36,701
38,304
38,696
43,018
46,701
57,267
Gross Income
38,475
34,854
35,964
36,703
35,684
34,646
SG&A Expense
40,236
37,684
34,336
38,386
34,436
36,150
EBIT
1,967
3,105
1,395
1,886
1,020
1,738
Unusual Expense
424
191
133
1,435
53
1,999
Non Operating Income/Expense
1,017
1,327
627
703
178
5,289
Interest Expense
1,813
1,564
1,423
1,396
1,467
1,689
Pretax Income
3,115
2,995
744
2,543
566
6,693
Income Tax
1,127
7,952
289
883
368
949
Consolidated Net Income
1,988
10,947
455
1,660
198
5,745
Net Income
1,988
10,947
455
1,660
198
5,745
Net Income After Extraordinaries
1,988
10,947
455
1,660
198
5,745
Net Income Available to Common
1,988
10,947
455
1,660
198
5,745
EPS (Basic)
110.00
589.00
23.00
83.00
10.00
257.76
Basic Shares Outstanding
18
19
20
20
20
22
EPS (Diluted)
107.36
579.30
22.89
83.29
9.69
293.07
Diluted Shares Outstanding
19
19
20
20
20
23
EBITDA
502
1,636
2,971
313
2,761
177
Other Operating Expense
206
275
233
202
228
234
Non-Operating Interest Income
73
155
12
8
6
24

About Dongsung Pharmaceutical Co.

View Profile
Address
683 Dobong-ro
Seoul SL 01340
Korea, Republic Of
Employees -
Website http://www.dongsung-pharm.co.kr
Updated 07/08/2019
Dongsung Pharmaceutical Co., Ltd. engages in the manufacture and distribution of pharmaceuticals. It operates through following business divisions: Pharmaceutical and Cosmetic. Its products include general and special medicines such anti-rheumatic and anti-inflammatory analgesics, anti-inflammatory enzymes, cardiovascular system, gastrintestinal drugs, antispasmodic agents, respiratory agents, anti-histamine, dematologicals, antibiotics, antidiarreals, antifungals, oral hypoglycemic agents, hormones and tranquillizers.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.